Gut microbiome in Phase I CRISPR-phage (SNIPR001) trial, USA
391 stool samples from healthy subjects in a US Phase I trial receiving a CRISPR-armed bacteriophage cocktail targeting E. coli (three dose levels) or placebo, twice daily for seven days, sampled at multiple time points. machine-written summary
391 samples · 391 runs · US · Age unknown · 2026 · 16.70 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 4,301 sample values (collection date, country, health condition, health condition detail, intervention, intervention detail, latitude, location region) |
| ✓ Abstract / description | 782 sample values (location locality, location site) |
| – Full text | no open-access full text linked |
| – Supplementary tables | no supplementary tables available (or none open access) |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention · arms resolved
Bacteriophage therapy design randomized_controlled_trial · population healthy_control · CRISPR-armed phage cocktail (SNIPR001) vs placebo, twice daily 7 days, 3 doses
“36 healthy subjects received a CRISPR-armed bacteriophage cocktail” — bioproject.description (study level; per-sample arms are in the intervention column below)
longitudinal — not resolved
36 of 36 people sampled more than once (391 samples; median 11, up to 11 per person). Schedule stated by the source: “Stool at multiple timepoints before, during and after treatment (days -1 to 187)” (time origin: intervention_start); stated follow-up 6 mo.
No Sandpiper profile for this project's samples yet.
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 0 | 0% | ||||
| country | 391 | 100% | 391 | |||
| health_condition | 391 | 100% | 391 | |||
| subject_id | 391 | 100% | 391 | |||
| collection_date | 391 | 100% | 391 | |||
| detailed_location | 391 | 100% | ||||
| health_condition_detail | 391 | 100% | 391 | |||
| intervention | 391 | 100% | 391 | |||
| intervention_detail | 391 | 100% | 391 | |||
| latitude | 391 | 100% | 391 | |||
| location_locality | 391 | 100% | 391 | |||
| location_region | 391 | 100% | 391 | |||
| location_site | 391 | 100% | 391 | |||
| longitude | 391 | 100% | 391 | |||
| timepoint_label | 391 | 100% | 391 |
- Safety, recovery, and pharmacodynamics of CRISPR-Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation study. 2026 PMID 41785880 own_data
Archive description
In a Phase I clinical trial, 36 healthy subjects received a CRISPR-armed bacteriophage cocktail targeting E. coli, administered twice daily for seven days at three different dose-levels (or placebo). Deep metagenomic sequencing of stool samples was performed at multiple time points, before, during, and after the treatment, to assess the potential impact on the microbiome.</p><p>Human genetic material has been eliminated.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of age unknown by opus_adjudicated with confidence 0.85. Assay shotgun_dna.
- host run.host_tax_id · “9606”
- host study.description · “36 healthy subjects”
- body site study.description · “metagenomic sequencing of stool samples”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN46716206 | collection_date | 2022 | R1 | 0.90 | biosample.attribute:collection_date | 2022 |
| SAMN46716206 | country | US | R1 | 0.90 | sample.attr.geo_loc_name | USA |
| SAMN46716206 | health_condition | healthy_control | R1 | 0.70 | sample.name_rule:alias | 001-003_cohort1_Placebo_Day-1 |
| SAMN46716206 | health_condition_detail | 001-003_cohort1_Placebo_Day-1 | R1 | 0.70 | sample.name_rule:alias | 001-003_cohort1_Placebo_Day-1 |
| SAMN46716206 | intervention | placebo | R1 | 0.90 | biosample.attribute:dose_level_pfu | dose_level_pfu: Placebo |
| SAMN46716206 | intervention_detail | placebo (no phage) | R1 | 0.90 | biosample.attribute:dose_level_pfu | dose_level_pfu: Placebo |
| SAMN46716206 | latitude | 39.1588 | R1 | 0.90 | biosample.attribute:lat_lon | 39.15876613 N 84.40207938 W |
| SAMN46716206 | location_locality | Cincinnati | R4 | 0.50 | paper.abstract | single centre (Medpace Clinical Pharmacology Unit; Cincinnati, OH, USA) |
| SAMN46716206 | location_region | Ohio | R1 | 0.60 | biosample.attribute:lat_lon | 39.15876613 N 84.40207938 W |
| SAMN46716206 | location_site | Medpace Clinical Pharmacology Unit | R4 | 0.50 | paper.abstract | single centre (Medpace Clinical Pharmacology Unit; Cincinnati, OH, USA) |
| SAMN46716206 | longitude | -84.4021 | R1 | 0.90 | biosample.attribute:lat_lon | 39.15876613 N 84.40207938 W |
| SAMN46716206 | subject_id | 001-003 | R1 | 0.85 | sample.attr.subject_id | 001-003 |
| SAMN46716206 | timepoint_label | -1 | R1 | 0.85 | sample.attr.day_of_study | -1 |
Sequencing
391 runs over 391 samples · mean 16.35 Gbp per run (median 16.70 Gbp, total 6,392.45 Gbp; 391 runs with a base count) · layout PAIRED 391 · platform ILLUMINA 391 · models Illumina NovaSeq 6000 (391) · 0% of runs with a Sandpiper profile · first public 2026-07-02
Authors (0)
No author record.
Downloads
PRJNA1220341.csv.gz (12.2 KB) · parquet (86.4 KB) — all 391 samples, every field with route and confidence · PRJNA1220341_determinations.csv.gz (36.6 KB) — 5,083 evidence rows